Intelligent Bio Solutions to Host Virtual Fireside Chat on September 24th at 4:30 p.m. ET

Management to discuss FDA 510(k) submission, clinical data, and commercial progress outside the U.S.

NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it will host a virtual fireside chat on Thursday, September 24, 2026, at 4:30 p.m. ET.

The moderated discussion will feature Harry Simeonidis, President and CEO, and Peter Passaris, Vice President of Product Development. Topics will include the Company’s FDA 510(k) submission for its Intelligent Fingerprinting Drug Screening System, the supporting clinical data, the FDA review process, and the Company’s commercial progress outside the United States.

Event Details

• Date: Thursday, September 24, 2026
• Time: 4:30 p.m. ET
• Format: Virtual fireside chat, followed by a live Q&A session
• Webcast Registration: https://us02web.zoom.us/webinar/register/WN_vWXs5KeQSYCxSxhmR5_bVQ

A live webcast of the event will be available through the registration link above. A replay of the presentation will be made available on the Company’s investor relations website following the event.

About Intelligent Bio Solutions Inc. 

Intelligent Bio Solutions Inc. (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.

For more information, visit: https://ibs.inc/

Company Contact 
Intelligent Bio Solutions Inc.   
[email protected]

Investor & Media Contact  
Valter Pinto, Managing Director   
KCSA Strategic Communications   
PH: (212) 896-1254   
[email protected] 

You May Also Be Interested In

• UPT to Launch Virtual IBAN Service to Simplify International Payments
• HepaRegeniX Completes Darizmetinib Treatment Phase for First Patient Undergoing Major Liver Resection in Phase 1b Liver Regeneration Study
• Focus Graphite Engages BBA for Environmental Field Program Supporting Lac Knife Access Road